GleamWall
中文EN

BIAF bioAffinity Technologies, Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1712762 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.5%
TTM net income YoY-4.6%
TTM EPS YoY182.9%
Revenue 3-yr CAGR37.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-246.1%
Net margin-278.9%
FCF margin-235.9%
EBITDA margin-239.5%

Returns

ROE-240.5%
ROA-161.4%
ROIC (approx.)-827.2%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets48.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-270.95x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$6.16M$9.36M
R&D expense$1.38M$1.46M
SG&A expense$9.91M$9.94M
Operating income-$10.57M-$8.95M
Interest expense$44,372$92,475
Pretax income-$14.87M-$9.03M
Income tax$44,042$11,650
Net income-$14.91M-$9.04M
EBITDA-$10.07M-$8.35M
EPS (basic)-8.66-22.50
EPS (diluted)-8.66-22.50
Weighted avg. shares (diluted)1.72M404,167
Balance sheet
Cash & equivalents$6.45M$1.11M
Inventory$53,548$27,608
Current assets$7.57M$2.70M
PP&E, net$265,593$375,385
Goodwill$1.40M$1.40M
Intangibles$716,806$775,139
Total assets$10.96M$6.51M
Current liabilities$2.91M$3.10M
Total liabilities$3.68M$3.91M
Shareholders' equity$7.28M$2.60M
Shares outstanding299,826519,158
Cash flow statement
Operating cash flow-$9.33M-$7.26M
Capital expenditure$60,568$79,083
Free cash flow-$9.39M-$7.34M
Investing cash flow-$60,568-$79,083
Financing cash flow$14.73M$5.63M
Depreciation & amortization$504,836$605,637
Stock-based compensation$671,474$989,681

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.